Investment Rating - The report gives a "Buy" rating for the company based on its business layout and growth potential [6] Core Insights - The company, Meili Tianyuan, is a leader in the beauty and health sector, leveraging a "Double Beauty + Double Health" model to create a value closed loop and drive long-term growth through both organic and external expansion [3][5] - The beauty industry in China has significant growth potential, with Meili Tianyuan holding a prominent market position, particularly in the traditional beauty and non-surgical medical beauty segments [4][38] Company Overview - Meili Tianyuan has established itself as a leading player in the beauty and health management sector, focusing on high-end clientele and offering a comprehensive service system [10] - The company operates under multiple brands, including Meili Tianyuan, Beili Shi, Xiuker, and others, and has made strategic acquisitions to enhance its market presence [3][10] Beauty Industry - The traditional beauty market in China is projected to grow from CNY 403.2 billion in 2021 to CNY 640.2 billion by 2030, with a CAGR of 5.3% [4][38] - The non-surgical medical beauty market is expected to expand significantly, with a projected CAGR of 17.46% from CNY 97.7 billion in 2021 to CNY 415.7 billion by 2030 [4][48] Financial Analysis - The company's revenue grew from CNY 1.405 billion in 2019 to CNY 1.781 billion in 2021, with a net profit increase from CNY 147 million to CNY 208 million during the same period [3][20] - The revenue forecast for 2025-2027 is CNY 30.11 billion, CNY 40.16 billion, and CNY 45.63 billion, respectively, with net profits projected at CNY 3.36 billion, CNY 4.51 billion, and CNY 5.37 billion [6][20] Core Highlights - The "Double Beauty + Double Health" model effectively addresses customer needs and enhances loyalty through a complete service cycle, from acquisition to retention [5][64] - The company has a strong focus on digital operations and refined membership management to expand its customer base and drive steady growth across its business lines [5][64]

Core Viewpoint - Meili Tianyuan Medical Health is expected to achieve significant revenue and profit growth in the first half of 2025, driven by both internal and external strategies [1][2] Group 1: Performance Forecast - The company anticipates revenue of no less than 1.45 billion yuan, representing a growth rate of at least 27% [1] - Adjusted net profit is projected to be no less than 175 million yuan, with a growth rate of at least 33% [1] - Net profit is expected to be no less than 170 million yuan, with a growth rate of at least 35% [1] Group 2: Internal and External Growth Strategies - Internal growth is supported by enhanced business models and operational efficiency, leveraging a unique commercial loop based on beauty services [1] - The company has invested in digital systems to improve standardized operational efficiency, facilitating rapid business model replication [1] - External growth is driven by a commitment to mergers and acquisitions to expand scale and integrate quality resources in the beauty industry [1] Group 3: Shareholder Confidence and Market Position - The company has optimized its shareholding structure, with early shareholder CPE reducing its stake by approximately 51.33 million shares (21.77% of total shares) [2] - A commitment to a dividend payout ratio of no less than 50% of net profit from 2025 to 2027 is expected to enhance shareholder returns [2] - The establishment of an equity incentive plan aims to align management interests with company growth, improving governance and development momentum [2] Group 4: Revenue and Profit Projections - Revenue projections for 2025-2027 are estimated at 3.064 billion, 3.344 billion, and 3.645 billion yuan, respectively [2] - Corresponding net profits for the same period are projected at 320 million, 362 million, and 413 million yuan [2] - The expected price-to-earnings ratios are 20, 18, and 16 times for the years 2025, 2026, and 2027, respectively [2]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase exceeding 15% over the next six months [6]. Core Insights - The company is projected to achieve a revenue of no less than 1.45 billion yuan in the first half of 2025, representing a growth rate of at least 27%. Adjusted net profit is expected to be no less than 175 million yuan, with a growth rate of at least 33% [1]. - The company's dual growth strategy, driven by both organic and external expansion, is effectively supporting steady revenue growth. Internally, the company is enhancing its business model and operational efficiency, while externally, it is committed to scaling through mergers and acquisitions [2]. - The optimization of the shareholding structure, high dividend commitments, and stock incentive plans reflect the company's confidence in its long-term development [3]. Financial Summary - The company’s projected revenues for 2025-2027 are 3.064 billion yuan, 3.344 billion yuan, and 3.645 billion yuan, respectively. Corresponding net profits are expected to be 320 million yuan, 362 million yuan, and 413 million yuan, with price-to-earnings ratios of 20, 18, and 16 times [3][5]. - The financial outlook shows a significant increase in revenue and net profit, with a projected revenue growth of 19.13% in 2025 and 9.13% in 2026 [5]. - The company is expected to maintain a dividend payout ratio of no less than 50% of net profit from 2025 to 2027, enhancing shareholder returns [3].